A pilot feasibility study published in Blood Neoplasia demonstrates the potential of comprehensive cfDNA + cfRNA liquid biopsy for molecular profiling in cutaneous T-cell lymphoma (CTCL). Using GTC’s high-depth NGS platform,
GTC will spotlight DNA and RNA-based precision oncology testing, liquid biopsy applications and research across hematologic malignancies, breast cancer metastasis and CNS involvement CHICAGO, May
Just published in The Journal of Liquid Biopsy Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic
Maher Albitar, Ahmad Charifa, Sally Agersborg, Andrew Pecora, Andrew Ip, Andre Goy Abstract: Most of the current utilization of liquid biopsy (LBx) is based on
Introducing a novel liquid biopsy approach combining cfRNA and cfDNA sequencing. Our findings demonstrate superior mutation detection with cfRNA, while cfDNA excels in identifying chromosomal aberrations. Elevated cfRNA biomarkers correlate with tumor types, aiding diagnosis. Machine learning predicts cancer types accurately. Host immune response analysis through cfRNA ratios reveals distinct patterns in cancer patients. This integrated approach holds promise for predicting genomic abnormalities and cancer diagnosis
Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA)
GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune
GTC presented abstracts at ASH 2022 GTC’s posters from 2022 Convention of American Society of Hematology are now available to be downloaded. Please reach out
In partnership with Anthology Diagnostics and Key Genomics, GTC presented four abstracts at ASH 2021 GTC’s posters from 2021 Convention of American Society of Hematology
Irvine, California– December 1, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH)
